The abstract is read at the publisher; the summary is JClub's.
TR-107 inhibits growth and viability of four pancreatic ductal adenocarcinoma (PDAC) organoids and four cell lines at low-nanomolar concentrations while downregulating ClpX expression dose-dependently.
- Why it matters: PDAC relies on mitochondrial pro-survival programs and metabolic reprogramming, so targeting mitochondrial homeostasis could address a key survival vulnerability.
- What they did: The study tested TR-107 across PDAC organoids and cell lines, measured viability and ClpX levels, performed transcriptomic profiling, assessed activity under hypoxia, and evaluated synergy with capivasertib.
- The result: TR-107 maintained efficacy and mechanism under hypoxic conditions and synergized with the AKT inhibitor capivasertib to suppress viability and alter downstream signaling, supporting combination opportunities in PDAC.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.